|
False Claims Act Update & Alert |
||||||||||||
|
Taxpayers Against Fraud Education Fund | Washington, D.C. | WWW.TAF.ORG February 8, 2008 |
||||||||||||
n TAF Home Page n Previous Newsletters n Email editor
|
|
|||||||||||
False Claims Act Update & Alert
Taxpayers Against Fraud Education Fund | Washington, D.C. | WWW.TAF.ORG February 8, 2008
n TAF Home Page
n Previous Newsletters
n Email editor
Please take a moment to forward this FREE electronic newsletter to others that might be interested!
Merck Settles for $650 Million
Merck has settled two False Claims Act cases related to the marketing top-selling drugs, Zocor, Vioxx and Pepcid. The scheme involved Merck offering 92% discounts to hospitals and clinics provided they filled their prescription needs with Merck product. Once patients left the hospital, it was expected they would continue to use the expensive drugs, with Medicare, Medicaid and private insurance paying the full price. Discounts tied to sales performance are considered a kickback and violation of Medicaid best-price rules. >> To read more
Alabama AWP Trial to Start
The State of Alabama is about to go to trial against 79 drug companies accused of price-gouging the state's Medicaid program. The alleged fraud is that the drugs companies vastly overstated the Average Wholesale Price of medicine and then concealed the price-gouging. >> To read more
"Undercover" by John Schilling
Columbia-HCA whistleblower John Schilling is coming out with a book recounting his experiences going from company man to FBI spy to help expose the worst healthcare fraud in U.S. history. Undercover will be published in April, but it can be pre-ordered now from Amazon or Barnes and Noble. John Schilling currently runs JWS Group, a forensic accounting firm that assists lawyers on complex health fraud cases.
Finally A Treatment
Finally a treatment for a disease that seems to be sweeping across the nation like a plague: Motivational Deficiency Disorder. Coffee is simply not doing it. To see this parody pharmaceutical company marketing video >> Click here
Lilly Sued Over Zyprexa as Settlement Rumors Swirl
Shareholders are suing Lilly for failing to disclose the risks of pushing off-label Zyprexa. The shareholders groups are saying Lilly should have known the FDA and others would crack down if the company promoted Zyprexa for unapproved uses. Meanwhile, The New York Times reports Lilly is in negotiations to settle an off-label Zyprexa FCA case for as much as $1 billion. How did the newspaper get this information? It turns out Lilly's lawyer accidentally emailed it to The New York Times. Ouch. Sales of Zyprexa topped $4.7 billion in 2007 alone. >> To read more